A Study of MT-0551 in Patients With Systemic Sclerosis

Summary

The study will verify the superiority of MT-0551 to placebo at 26 weeks after treatment initiation in systemic sclerosis (SSc) patients using the modified Rodnan Total Skin thickness Score (mRTSS) as a measure of skin thickening. The safety and pharmacokinetics will also be investigated.

Timeline

Start

2022-07-20

Primary completion

2025-07-31

Completion

2026-08

Drugs

Indications